The Federal Commission for the Protection against Sanitary Risk (Cofepris) announced that the laboratories Pfizer and Moderna, which sought health registrations for their vaccines against the SARS-CoV-2 virus, requested more time to provide the missing technical information in their respective files.
Due to this extension request, the evaluation process has not yet concluded. On November 22, the health agency had requested additional data from both companies, which were expected to complete the applications. It was planned that today the final ruling would be revealed for the release of the registrations.
Once authorized, the vaccines from Pfizer (Comirnaty) and Moderna (Spikevax monovalent through its legal representative in Mexico, Asofarma SA de CV) will be able to be marketed in the country's private sector.
So far, both vaccines maintain their emergency use registration. Cofepris highlighted its interest in evaluating these health products as a priority, and the group of reviewers assigned to this task is waiting to receive the elements that the laboratories must provide to support their requests.
Furthermore, the Commission reiterated the message to the population that the coronavirus vaccine is universal and free, and warned about the health risks associated with its indiscriminate use.
With information from: La Jornada.
Receive all industry news in our weekly Newsletter Scientific Dialectics.